The Enteric Nervous System & Peptide Signaling

The enteric nervous system (ENS) is a vast neural network embedded within the gastrointestinal tract walls, extending from esophagus to rectum. Containing approximately 500 million neurons — more than the spinal cord — the ENS coordinates motor, secretory, and immune activities required for digestion and communicates bidirectionally with the brain through the vagus nerve and spinal afferents. Peptide neurotransmitters are the primary chemical language of this system.

Architecture of the ENS

The ENS is organized into two major plexuses. The myenteric (Auerbach's) plexus lies between the longitudinal and circular muscle layers, primarily controlling gut motility. The submucosal (Meissner's) plexus regulates mucosal secretion, blood flow, and epithelial function.

These plexuses contain sensory neurons (detecting distension, chemical stimuli, and mucosal damage), interneurons (processing and relaying information), and motor neurons (activating smooth muscle, secretory cells, and blood vessels). This complete sensory-integrative-motor circuit allows the ENS to function as a self-contained reflex system — unique among peripheral nervous system structures.

While acetylcholine and nitric oxide serve as primary excitatory and inhibitory neurotransmitters for motor function, the nuanced regulation of gut physiology depends heavily on peptide co-transmitters that modulate and coordinate enteric circuit activity.

Key peptide signals

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide functioning as the primary inhibitory peptide neurotransmitter in the ENS. VIP relaxes circular smooth muscle (essential for receptive relaxation and descending relaxation ahead of peristaltic waves), stimulates water and electrolyte secretion, dilates mesenteric blood vessels, and exerts anti-inflammatory effects on mucosal immune cells.

Substance P, an 11-amino-acid tachykinin acting through NK1 receptors, is the primary excitatory peptide. It contracts circular smooth muscle, promotes secretion, and has potent pro-inflammatory effects — stimulating mast cell degranulation and cytokine release. The balance between VIP and substance P signaling is a key determinant of gut homeostasis, and its disruption is implicated in inflammatory bowel disease and irritable bowel syndrome.

GLP-1 is produced by enteroendocrine L-cells in the distal intestine. It potentiates insulin secretion, slows gastric emptying, and reduces appetite. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) represent one of the most successful applications of peptide signaling biology. GLP-1 receptors are also expressed on vagal afferent neurons and throughout the brain, mediating gut-derived satiety signaling.

BPC-157 is a 15-amino-acid peptide derived from human gastric juice with cytoprotective and healing-promoting effects in preclinical gut injury models. Its mechanism appears to involve nitric oxide signaling modulation and dopamine system interactions. While its precise receptor target remains under investigation, its effects on motility, mucosal healing, and inflammation resolution are consistent with action within enteric neuropeptide networks.

The gut-brain axis

The ENS communicates with the central nervous system through parallel pathways.

Vagal afferents are the primary neural route — approximately 80% of vagal fibers are afferent (gut-to-brain), transmitting information to the brainstem. Enteric peptides — GLP-1, cholecystokinin (CCK), and peptide YY (PYY) — activate vagal terminals in the gut wall, relaying signals about nutrient content, distension, and inflammation to central circuits regulating appetite, mood, and autonomic tone.

Spinal afferents primarily convey pain signals, mediated by substance P and CGRP. These pathways are a key target in functional gastrointestinal disorders.

Humoral signaling provides a parallel route. Gut peptides released into portal circulation reach the brainstem through circumventricular organs where the blood-brain barrier is relatively permeable, or act on peripheral receptors that relay signals centrally.

The gut microbiome adds further complexity — microbial metabolites influence enteric peptide release from enteroendocrine cells and modulate ENS neurotransmission through the microbial-enteric-central axis.

Therapeutic relevance

GLP-1 receptor agonists directly leverage ENS-mediated gastric emptying slowing and vagal-mediated appetite suppression. Their gastrointestinal side effects (nausea, altered bowel habits) are direct consequences of activity within enteric circuits — pharmacological effects, not off-target toxicity.

Oral peptide delivery also intersects with ENS biology. The gut epithelium is simultaneously the major barrier to peptide absorption and an active peptide-signaling organ. For peptides like BPC-157 administered orally, the primary site of action may be the enteric nervous system and gut mucosa rather than systemic targets — potentially explaining biological effects at doses too low for meaningful systemic concentrations.